Akers Biosciences (NASDAQ:AKER) and Vermillion (NASDAQ:VRML) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, analyst recommendations, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares Akers Biosciences and Vermillion’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Akers Biosciences $1.67 million 6.35 -$10.85 million N/A N/A
Vermillion $3.05 million 32.19 -$11.37 million N/A N/A

Akers Biosciences has higher earnings, but lower revenue than Vermillion.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Akers Biosciences and Vermillion, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akers Biosciences 0 0 0 0 N/A
Vermillion 0 1 0 0 2.00

Vermillion has a consensus target price of $2.25, indicating a potential upside of 73.08%. Given Vermillion’s higher possible upside, analysts clearly believe Vermillion is more favorable than Akers Biosciences.

Volatility & Risk

Akers Biosciences has a beta of -0.93, meaning that its share price is 193% less volatile than the S&P 500. Comparatively, Vermillion has a beta of 3.7, meaning that its share price is 270% more volatile than the S&P 500.

Profitability

This table compares Akers Biosciences and Vermillion’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Akers Biosciences -651.26% -121.41% -100.32%
Vermillion -372.45% -150.85% -97.95%

Institutional and Insider Ownership

8.4% of Akers Biosciences shares are held by institutional investors. Comparatively, 20.9% of Vermillion shares are held by institutional investors. 8.9% of Akers Biosciences shares are held by insiders. Comparatively, 4.3% of Vermillion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Vermillion beats Akers Biosciences on 7 of the 10 factors compared between the two stocks.

About Akers Biosciences

Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol ‘Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth ‘Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.

About Vermillion

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.

Receive News & Ratings for Akers Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.